Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aquestive Therapeutics Inc AQST

Healthcare
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on... see more

Recent & Breaking News (NDAQ:AQST)

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Aquestive Therapeutics, Inc. (AQST) Investigation

ACCESSWIRE IA September 30, 2020

Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant(TM) (diazepam) Buccal Film for Management of Seizure Clusters

GlobeNewswire September 25, 2020

Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including Anaphylaxis

GlobeNewswire August 20, 2020

Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis

GlobeNewswire August 10, 2020

Aquestive Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update: AQST-108 Progress Remains On Track; Libervant PDUFA Goal Date Approaches

GlobeNewswire August 4, 2020

Aquestive Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

GlobeNewswire July 28, 2020

Aquestive Therapeutics to Announce Second Quarter Financial Results and Recent Business Highlights on Aug 4 and Host Conference Call on Aug 5 at 8:00 a.m. ET

GlobeNewswire July 15, 2020

Aquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment

GlobeNewswire June 29, 2020

Aquestive Therapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference

GlobeNewswire June 16, 2020

Aquestive Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders

GlobeNewswire June 4, 2020

Aquestive Therapeutics Advances Royalty Monetization Plan as Sunovion Pharmaceuticals' Apomorphine Sublingual Film Therapy Receives FDA Approval

GlobeNewswire May 21, 2020

Aquestive Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 7, 2020

Aquestive Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update: AQST-108 and Libervant Remain On Track

GlobeNewswire May 5, 2020

Aquestive Therapeutics to Announce First Quarter Financial Results and Recent Business Highlights on May 5 and Host Investment Community Conference Call on May 6

GlobeNewswire April 21, 2020

Memgen Appoints Gregory Brown as Chief Executive Officer

Newsfile March 17, 2020

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

GlobeNewswire March 11, 2020

Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights on March 12, 2020

GlobeNewswire February 20, 2020

Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant(TM) (diazepam) Buccal Film

GlobeNewswire February 10, 2020

Aquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment

GlobeNewswire February 6, 2020

Aquestive Therapeutics Receives FDA Response to Citizen's Petition

GlobeNewswire January 12, 2020